This BONUS lecture was a talk given to the Hematology/Oncology fellows at Oregon Health & Science University. It's part three of a three-part series on clinical trials. 

Back us on Patreon! www.patreon.com/plenarysession

2.51 BONUS! Clinical Trials Part 3

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Patient advocates, Pharma funding, and is MRD a suitable endpoint

Patient advocates funded by Pharma

FDA makes MRD the basis for AA

Another flawed quality metric. Reviewing the NEJM paper "Beta-Blockers After Myocardial Infarction and Preserved Ejection Fraction".

Beta Blockers After Heart Attacks Don't Work

Blood based and Stool DNA colon cancer screening - Two NEJM papers

Another flawed study Keynote 564. Pembro in adjuvant RCC

2.51 BONUS! Clinical Trials Part 3

Download our free app to listen on your phone